Log in or Sign up for Free to view tailored content for your specialty!
Dermatitis News
Learning disabilities associated with atopic dermatitis severity in children
Atopic dermatitis severity is associated with learning disabilities in children, according to a study.
Abrocitinib priority review for atopic dermatitis extended
The FDA has extended the priority review period for abrocitinib’s New Drug Application for the treatment of moderate to severe atopic dermatitis, Pfizer announced in a press release.
Log in or Sign up for Free to view tailored content for your specialty!
Abrocitinib improves atopic dermatitis signs, symptoms
Both 100 mg and 200 mg doses of once-daily abrocitinib improved signs and symptoms in patients with moderate to severe atopic dermatitis, according to a study.
Broad spectrum of comorbidities may be common in children with atopic dermatitis
Children with atopic dermatitis were more likely to experience a broad array of comorbidities than matched controls, from mental health conditions such as anxiety to dermatologic complications such as vitiligo, according to a study.
Baricitinib 2 mg shows positive phase 3 results in atopic dermatitis
Patients with moderate to severe atopic dermatitis experienced statistically significant improvement with baricitinib 2 mg, according to a phase 3 study.
Children with atopic dermatitis more likely to have chronic school absenteeism
Chronic school and work absenteeism is more common in children with atopic dermatitis and their caregivers than in those with psoriasis, according to a study.
FDA extends review period for expanded use of Rinvoq in PsA to assess risk-benefit
The FDA has extended its review period for the supplemental new drug application of AbbVie’s upadacitinib for active psoriatic arthritis to allot more time to examine its risk-benefit profile, according to a company press release.
Abrocitinib plus topical therapy effective in adolescents with atopic dermatitis
Abrocitinib combined with a medicated topical therapy was effective, well tolerated and improved quality of life in adolescents with atopic dermatitis, according to phase 3 results from the JADE TEEN Study.
Ruxolitinib cream has antipruritic, anti-inflammatory mode of action in atopic dermatitis
Ruxolitinib demonstrated efficacy and a dual mode of action among patients with atopic dermatitis, according to a poster at South Beach Symposium Medical Dermatology Summit.
Anti-OX40 antibody shows efficacy in atopic dermatitis treatment
Kyowa Kirin reported positive phase 2 study results for KHK4083 in treating atopic dermatitis compared with placebo, according to a press release.
-
Headline News
We must make our voices heard and vote in the 2024 election
September 18, 20247 min read -
Headline News
Semaglutide improves glucose control in automated insulin delivery for type 1 diabetes
September 20, 20243 min read -
Headline News
Oncologists, primary care clinicians should be aware of BRCA testing indications in men
September 19, 20244 min read
-
Headline News
We must make our voices heard and vote in the 2024 election
September 18, 20247 min read -
Headline News
Semaglutide improves glucose control in automated insulin delivery for type 1 diabetes
September 20, 20243 min read -
Headline News
Oncologists, primary care clinicians should be aware of BRCA testing indications in men
September 19, 20244 min read